Search clinical trials for: AZD4017

Total 83 results

AstraZeneca

Completed

Study to Evaluate Methods That Assess the Effect of AZD4017 in Adipose Tissue

Obesity

Sweden
AstraZeneca

Completed

Phase I Study in Healthy Volunteers to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD4017 After Repeated Ascending Oral Doses (MAD)

Diabetes Mellitus Type 2

Sweden
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017

Healthy

Sweden
AstraZeneca

Completed

Study to Investigate Safety and Tolerability Single Ascending Doses of AZD4017.

Healthy

Japan
University of Birmingham

Completed

Safety and Effectiveness of 11b-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) to Treat Idiopathic Intracranial Hypertension. (IIH:DT)

Idiopathic Intracranial Hypertension

United Kingdom
University of Leeds

Completed

Glucocorticoids and Skin Healing in Diabetes (GC-SHealD) (GC-SHealD)

Diabetes Mellitus, Type 2

United Kingdom
Samsung Medical Center

Withdrawn

Phase II Trial of Vistusertib（AZD2014） Single Agent in TSC1or 2 Null or TSC 1/2 Mutation Solid Cancer Patients Refractory to Standard Chemotherapy (TSC1/2_SC)

Solid Tumor

Korea, Republic of
National Cancer Institute (NCI)

Completed

Testing AZD4547 as a Potential Targeted Treatment in Cancers With FGFR Genetic Changes (MATCH-Subprotocol W)

Hematopoietic and Lymphoid Cell Neoplasm | Advanced Lymphoma | Advanced Malignant Solid Neoplasm | Refractory Lymphoma | Refractory Malignant Solid Neoplasm | Refractory Plasma Cell Myeloma

United States
Massachusetts General Hospital
United States Department of Defense; AstraZeneca

Completed

AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas

Meningioma | Neurofibromatosis 2

United States
AstraZeneca

Completed

A Phase I, Dose-Escalation Study to Assess the Safety and Drug Levels in Blood of AZD4877 in Japanese Adult Patients

Carcinoma | Cancer | Tumors

Japan
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of Safety and Efficiency of AND017 in Patients With Transfusion Dependent and Non-transfusion Dependent β-thalassemia

β -Thalassemia
AstraZeneca

Completed

Study to Assess Safety and Tolerability of AZD4547 in Japanese Patient

Cancer | Advanced Solid Malignancies

Japan
AstraZeneca

Terminated

Phase I, Open-label, Dose Escalation of AZD4877 in Hematologic Malignancies

Lymphoma

United States, Canada
AstraZeneca

Terminated

Phase I/II, Open-label, Multi-center, Two Part Dose-escalation, Safety, Pharmacokinetics (PK) and Efficacy Study of AZD4877 in Patients With Acute Myelogenous Leukemia (AML)

Acute Myelogenous Leukemia

United States, Canada
AstraZeneca

Completed

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder

United States, United Kingdom, Germany
AstraZeneca

Terminated

Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours

Cancer | Advanced Solid Malignancies

United States, Italy, United Kingdom, France, Germany, Spain, Netherlands
AstraZeneca

Terminated

Phase I, Open-label, Dose-escalation, Safety and PK Study of AZD4877

Lymphoma | Non-Hodgkin Lymphoma | NHL

United States
AstraZeneca

Completed

Phase I, Open-Label, Dose-Escalation Study of AZD4877 in Solid Tumors

Neoplasms

United States
Massachusetts General Hospital
National Cancer Institute (NCI); AstraZeneca

Active, not recruiting

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Meningioma

United States
AstraZeneca
National Institutes of Health (NIH); Eolas Therapeutics INC.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD4041 in Healthy Volunteers

Smoking Cessation

United States
Samsung Medical Center
AstraZeneca

Terminated

Vistusertib (AZD2014) Monotherapy in Relapsed Small Cell Lung Cancer Patients Harboring RICTOR Amplification ([SUKSES-D])

Small Cell Lung Cancer

Korea, Republic of
AstraZeneca

Completed

Tolerability/Safety and Efficacy of Inhaled AZD4818 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (TOP)

Chronic Obstructive Pulmonary Disease (COPD)

Sweden, Denmark, Finland, Netherlands, Norway
AstraZeneca

Active, not recruiting

A Study to Assess the Safety and Tolerability of Single Doses of AZD4076 in Healthy Male Subjects

Non-alcoholic Steatohepatitis (NASH)

United States
AstraZeneca

Completed

Safety, Tolerability and Pharmacokinetics of Inhaled Doses of AZD4818 in Healthy Japanese Male Volunteers

Healthy

Japan
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Urothelial Carcinoma

China
AstraZeneca

Withdrawn

Assessment of the Safety and Pharmacokinetics of Single and Multiple Oral Doses of AZD4316 in Healthy Subjects

Healthy Volunteers

United Kingdom
Kind Pharmaceuticals LLC

Completed

A Dose-escalation Study of AND017 in Healthy Subjects

Healthy Volunteers

Australia
Samsung Medical Center

Withdrawn

Phase II Trial of AZD2014 in RICTOR Amplified Solid Cancer Patients Refractory to Standard Chemotherapy (RICTOR_SC)

Solid Tumor

Korea, Republic of
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of Efficacy and Safety of AND017 in Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes
Kind Pharmaceuticals LLC

Completed

A Food-Effect Study of AND017 in Healthy Participants

Healthy Volunteers

China
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of AND017 in Cancer Related Anemic Patients Receiving Chemotherapy

Chemotherapy Induced Anemia
Kind Pharmaceuticals LLC

Not yet recruiting

A Study of AND017 to Treat Cancer Related Anemia in Patients Not Receiving Chemotherapy

Cancer-Related Anemia
Abbisko Therapeutics Co, Ltd

Completed

ABSK091 Food Effect Study in Healthy Subjects

Health, Subjective | Food-drug Interaction

Taiwan
Kind Pharmaceuticals LLC

Completed

A Study of AND017 to Treat Anemia in Non-dialysis-Dependent Chronic Kidney Disease (NDD-CKD) Patients

Renal Anemia

China, United States
AstraZeneca

Withdrawn

AZD2014 Plus Novel Anti-Cancer Agents in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (INHIBITOR)

Core: Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Module 1: Non-GCB Diffuse Large B-Cell Lymphoma
Royal Marsden NHS Foundation Trust
AstraZeneca; Institute of Cancer Research, United Kingdom

Completed

A Phase I Trial of the Combination of AZD2014 and Weekly Paclitaxel. (TAX-TORC)

Advanced Cancer

United Kingdom
Canadian Cancer Trials Group
AstraZeneca

Completed

mTORC1/mTORC2 Kinase Inhibitor AZD2014 in Previously Treated Glioblastoma Multiforme

Glioblastoma Multiforme

Canada
AstraZeneca

Completed

A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

Bladder Cancer | Urethra Cancer | Ureter Cancer | Renal Pelvis Cancer | Transitional Cell Bladder Cancer

United States, Spain, United Kingdom, Germany, Canada
AstraZeneca

Active, not recruiting

Japanese Phase I Study of AZD2014 in Advanced Solid Malignancies

Advanced Solid Malignancies

Japan
AstraZeneca

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD5718 After Single and Multiple Ascending Dose Administration to Healthy Japanese Men

Coronary Artery Disease

United States
AstraZeneca

Completed

A Phase IIa Study to Assess the Tolerability, Safety, and Efficacy of AZD4017 for Raised Intra-ocular Pressure

Raised Intraocular Pressure

Sweden, United States, United Kingdom
AstraZeneca
Altasciences Company Inc.

Completed

A Safety Study of AZD4041 in Healthy Participants

Opioid Use Disorder (OUD)

Canada
University of Birmingham
Pfizer; AstraZeneca; Mirati Therapeutics Inc.; Cancer Research UK; Experimental Cancer...

Active, not recruiting

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Adenocarcinoma | Carcinoma, Squamous Cell | Non-Small Cell Lung Cancer

United Kingdom
Imperial College London
AstraZeneca; Medical Research Council; National Institute for Health Research...

Completed

Neuropeptide Treatment for Hot Flushes During the Menopause (NK3R)

Menopausal Flushing

United Kingdom
AstraZeneca

Completed

AZD4076 in Type 2 Diabetic Subjects With Non-Alcoholic Fatty Liver Disease.

T2DM With NAFLD
Samsung Medical Center

Terminated

Phase II Trial of AZD2014 in TSC1/2 Mutated or TSC1/2 Null GC Patients as Second-line Chemotherapy

Cancer of Stomach

Korea, Republic of
Samsung Medical Center

Terminated

Trial of Single Agent AZD2014 in RICTOR Amplified GC Patients as Second-line Therapy (AZD2014)

Stomach Neoplasms

Korea, Republic of
Cambridge University Hospitals NHS Foundation Trust
AstraZeneca

Completed

Investigating the Effects of AZD2014 Therapy Given Prior to Radical Prostatectomy in Men With High Risk Prostate Cancer (CaNCaP02)

Prostate Cancer

United Kingdom
AstraZeneca

Completed

Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Efficacy of AZD2014

Advanced Solid Malignancies

United Kingdom
UNICANCER
AstraZeneca; Intergroupe Francophone de Cancerologie Thoracique; Fondation ARC

Completed

SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients (SAFIR02_Lung)

Non-small Cell Lung Cancer Metastatic

France

3

Subscribe